SEARCH

SEARCH BY CITATION

References

  • 1
    Walshe JM,Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis 2005; 22: 3544.
  • 2
    Kleer CG,van Golen KL,Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000; 2: 4239.
  • 3
    McCarthy NJ,Yang X,Linnoila IR,Merino MJ,Hewitt SM,Parr AL,Paik S,Steinberg SM,Hartmann DP,Mourali N,Levine PH,Swain SM. Microvessel density, expression of estrogen receptor α, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002; 8: 385762.
  • 4
    Levine PH,Steinhorn SC,Ries LG,Aron JL. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 1985; 74: 2917.
  • 5
    van Golen KL,Davies S,Wu ZF,Wang Y,Bucana CD,Root H,Chandrasekharappa S,Strawderman M,Ethier SP,Merajver SD. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5: 251119.
  • 6
    Bertucci F,Finetti P,Rougemont J,Charafe-Jauffret E,Nasser V,Loriod B,Camerlo J,Tagett R,Tarpin C,Houvenaeghel G,Nguyen C,Maraninchi D, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64: 855865.
  • 7
    Van Laere S,Van der Auwera I,Van den Eynden GG,Fox SB,Bianchi F,Harris AL,van Dam P,Van Marck EA,Vermeulen PB,Dirix LY. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005; 93: 23746.
  • 8
    Nguyen DM,Sam K,Tsimelzon A,Li X,Wong H,Mohsin S,Clark GM,Hilsenbeck SG,Elledge RM,Allred DC,O'Connell P,Chang JC. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006; 12: 504754.
  • 9
    Kleer CG,van Golen KL,Braun T,Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001; 14: 45864.
  • 10
    Sugiyama Y,Farrow B,Murillo C,Li J,Watanabe H,Sugiyama K,Evers BM. Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 2005; 128: 4806.
  • 11
    Coussens LM,Werb Z. Inflammation and cancer. Nature 2002; 420: 8607.
  • 12
    Orimo A,Gupta PB,Sgroi DC,Arenzana-Seisdedos F,Delaunay T,Naeem R,Carey VJ,Richardson AL,Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 33548.
  • 13
    Schor SL,Haggie JA,Durning P,Howell A,Smith L,Sellwood RA,Crowther D. Occurrence of a fetal fibroblast phenotype in familial breast cancer. Int J Cancer 1986; 37: 8316.
  • 14
    Hunter KW,Crawford NP. Germ line polymorphism in metastatic progression. Cancer Res 2006; 66: 12514.
  • 15
    Boersma BJ,Howe TM,Goodman JE,Yfantis HG,Lee DH,Chanock SJ,Ambs S. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006; 98: 91119.
  • 16
    Chang S,Parker SL,Pham T,Buzdar AU,Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 1998; 82: 236672.
  • 17
    Dumur CI,Garrett CT,Archer KJ,Nasim S,Wilkinson DS,Ferreira-Gonzalez A. Evaluation of a linear amplification method for small samples used on high-density oligonucleotide microarray analysis. Anal Biochem 2004; 331: 31421.
  • 18
    Tusher VG,Tibshirani R,Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 511621.
  • 19
    Tibshirani R,Hastie T,Narasimhan B,Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 656772.
  • 20
    Yi M,Horton JD,Cohen JC,Hobbs HH,Stephens RM. WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 2006; 7: 30.
  • 21
    Prueitt RL,Boersma BJ,Howe TM,Goodman JE,Thomas DD,Ying L,Pfiester CM,Yfantis HG,Cottrell JR,Lee DH,Remaley AT,Hofseth LJ, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007; 120: 796805.
  • 22
    Korn EL,McShane LM,Troendle JF,Rosenwald A,Simon R. Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002; 86: 10936.
  • 23
    Jeffrey KL,Brummer T,Rolph MS,Liu SM,Callejas NA,Grumont RJ,Gillieron C,Mackay F,Grey S,Camps M,Rommel C,Gerondakis SD, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 2006; 7: 27483.
  • 24
    Hlubek F,Jung A,Kotzor N,Kirchner T,Brabletz T. Expression of the invasion factor laminin γ2 in colorectal carcinomas is regulated by β-catenin. Cancer Res 2001; 61: 808993.
  • 25
    Yamamoto H,Itoh F,Iku S,Hosokawa M,Imai K. Expression of the γ(2) chain of laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Clin Cancer Res 2001; 7: 896900.
  • 26
    Katayama M,Sanzen N,Funakoshi A,Sekiguchi K. Laminin γ2-chain fragment in the circulation: a prognostic indicator of epithelial tumor invasion. Cancer Res 2003; 63: 2229.
  • 27
    Yin JJ,Mohammad KS,Kakonen SM,Harris S,Wu-Wong JR,Wessale JL,Padley RJ,Garrett IR,Chirgwin JM,Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 109549.
  • 28
    Wulfing P,Diallo R,Kersting C,Wulfing C,Poremba C,Rody A,Greb RR,Bocker W,Kiesel L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 2003; 9: 412531.
  • 29
    Grinberg I,Millen KJ. The ZIC gene family in development and disease. Clin Genet 2005; 67: 290296.
  • 30
    Biunno I,Cattaneo M,Orlandi R,Canton C,Biagiotti L,Ferrero S,Barberis M,Pupa SM,Scarpa A,Menard S. SEL1L a multifaceted protein playing a role in tumor progression. J Cell Physiol 2006; 208: 2338.
  • 31
    Vuillermoz B,Khoruzhenko A,D'Onofrio MF,Ramont L,Venteo L,Perreau C,Antonicelli F,Maquart FX,Wegrowski Y. The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 2004; 296: 294306.
  • 32
    Troup S,Njue C,Kliewer EV,Parisien M,Roskelley C,Chakravarti S,Roughley PJ,Murphy LC,Watson PH. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003; 9: 20714.
  • 33
    Koblinski JE,Kaplan-Singer BR,VanOsdol SJ,Wu M,Engbring JA,Wang S,Goldsmith CM,Piper JT,Vostal JG,Harms JF,Welch DR,Kleinman HK. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005; 65: 73707.
  • 34
    Kurochkin IV,Yonemitsu N,Funahashi SI,Nomura H. ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. Biochem Biophys Res Commun 2001; 280: 3407.
  • 35
    Armes JE,Hammet F,de Silva M,Ciciulla J,Ramus SJ,Soo WK,Mahoney A,Yarovaya N,Henderson MA,Gish K,Hutchins AM,Price GR, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 2004; 23: 5697702.
  • 36
    Pils D,Horak P,Gleiss A,Sax C,Fabjani G,Moebus VJ,Zielinski C,Reinthaller A,Zeillinger R,Krainer M. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 2005; 104: 241729.
  • 37
    Flemming A,Brummer T,Reth M,Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol 2003; 4: 3843.
  • 38
    Ballif BA,Mincek NV,Barratt JT,Wilson ML,Simmons DL. Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Proc Natl Acad Sci USA 1996; 93: 55449.
  • 39
    Pyke C,Salo S,Ralfkiaer E,Romer J,Dano K,Tryggvason K. Laminin-5 is a marker of invading cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995; 55: 41329.
  • 40
    Bieche I,Lerebours F,Tozlu S,Espie M,Marty M,Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004; 10: 678995.
  • 41
    Dressman HK,Hans C,Bild A,Olson JA,Rosen E,Marcom PK,Liotcheva VB,Jones EL,Vujaskovic Z,Marks J,Dewhirst MW,West M, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006; 12: 81926.
  • 42
    Van Laere SJ,Van der Auwera I,Van den Eynden GG,Elst HJ,Weyler J,Harris AL,van Dam P,Van Marck EA,Vermeulen PB,Dirix LY. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 2006; 12: 324956.
  • 43
    Van der Auwera I,Van Laere SJ,Van den Eynden GG,Benoy I,van Dam P,Colpaert CG,Fox SB,Turley H,Harris AL,Van Marck EA,Vermeulen PB,Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10: 796571.
  • 44
    Bertucci F,Finetti P,Rougemont J,Charafe-Jauffret E,Cervera N,Tarpin C,Nguyen C,Xerri L,Houlgatte R,Jacquemier J,Viens P,Birnbaum D. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005; 65: 21708.
  • 45
    Van Laere SJ,Van den Eynden GG,Van der Auwera I,Vandenberghe M,van Dam P,Van Marck EA,van Golen KL,Vermeulen PB,Dirix LY. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95: 24355.
  • 46
    Denoyelle C,Abou-Rjaily G,Bezrookove V,Verhaegen M,Johnson TM,Fullen DR,Pointer JN,Gruber SB,Su LD,Nikiforov MA,Kaufman RJ,Bastian BC, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006; 8: 105363.
  • 47
    Ma XJ,Wang Z,Ryan PD,Isakoff SJ,Barmettler A,Fuller A,Muir B,Mohapatra G,Salunga R,Tuggle JT,Tran Y,Tran D, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 60716.
  • 48
    Van de Vijver MJ,He YD,Van't Veer LJ,Dai H,Hart AA,Voskuil DW,Schreiber GJ,Peterse JL,Roberts C,Marton MJ,Parrish M,Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 19992009.
  • 49
    van 't Veer LJ,Dai H,Van de Vijver MJ,He YD,Hart AA,Mao M,Peterse HL,van der KK,Marton MJ,Witteveen AT,Schreiber GJ,Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 5306.
  • 50
    Chang HY,Nuyten DS,Sneddon JB,Hastie T,Tibshirani R,Sorlie T,Dai H,He YD,Van't Veer LJ,Bartelink H,Van De RM,Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 373843.
  • 51
    Perou CM,Sorlie T,Eisen MB,Van De RM,Jeffrey SS,Rees CA,Pollack JR,Ross DT,Johnsen H,Akslen LA,Fluge O,Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 74752.
  • 52
    Sorlie T,Perou CM,Tibshirani R,Aas T,Geisler S,Johnsen H,Hastie T,Eisen MB,Van De RM,Jeffrey SS,Thorsen T,Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 1086974.
  • 53
    Gruvberger S,Ringner M,Chen Y,Panavally S,Saal LH,Borg A,Ferno M,Peterson C,Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 597984.
  • 54
    Sotiriou C,Neo SY,McShane LM,Korn EL,Long PM,Jazaeri A,Martiat P,Fox SB,Harris AL,Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 1039398.
  • 55
    Ma XJ,Salunga R,Tuggle JT,Gaudet J,Enright E,McQuary P,Payette T,Pistone M,Stecker K,Zhang BM,Zhou YX,Varnholt H, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 59749.
  • 56
    Sorlie T,Tibshirani R,Parker J,Hastie T,Marron JS,Nobel A,Deng S,Johnsen H,Pesich R,Geisler S,Demeter J,Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 841823.